Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

KSQ Ther­a­peu­tics quick­ly lined up an­oth­er Big Phar­ma part­ner­ship, this time al­ly­ing with Roche in on­col­o­gy, and it plans to use the cash wind­fall to fund a clin­i­cal en­try next year for its in­ter­nal TIL cell ther­a­pies.

The Lex­ing­ton, MA-based biotech said Thurs­day it is out-li­cens­ing its clin­i­cal-stage small mol­e­cule in­hibitor KSQ-4279 in ex­change for a “very nice up­front and very nice short-term mile­stones,” as well as po­ten­tial roy­al­ties, KSQ CEO Qasim Rizvi told End­points News. Roche nabbed the world­wide rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER